NCT01177020

Brief Summary

Identification of the presence of proangiogenic immune cells in normal human placentas may enable predication of some pregnancy disorders.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2010

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 12, 2010

Completed
3 months until next milestone

Study Start

First participant enrolled

August 1, 2010

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 6, 2010

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

August 6, 2010

Status Verified

August 1, 2010

Enrollment Period

1 year

First QC Date

May 12, 2010

Last Update Submit

August 5, 2010

Conditions

Fetal Growth RetardationPreeclampsia

Outcome Measures

Primary Outcomes (1)

  • To find the angiogenic potential of proangiogenic immune cells derived from human placentas.

    Two years

Study Arms (1)

Placentas after delivery or abortion

Other: Biological specimen

Interventions

Biological specimenOTHER

Biological specimen taken from placenta

Placentas after delivery or abortion

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Placentas after delivery or abortion

You may qualify if:

  • Placentas that have been delivered in the Medical Center

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hillel Yaffe Medical Center

Hadera, 38100, Israel

RECRUITING

MeSH Terms

Conditions

Fetal Growth RetardationPre-Eclampsia

Interventions

Biological Specimen Banks

Condition Hierarchy (Ancestors)

Fetal DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGrowth DisordersPathologic ProcessesPathological Conditions, Signs and SymptomsHypertension, Pregnancy-Induced

Intervention Hierarchy (Ancestors)

Health FacilitiesHealth Care Facilities Workforce and Services

Central Study Contacts

Elad Mei-Dan, MD

CONTACT

972-4-6304248eladmei@yahoo.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

May 12, 2010

First Posted

August 6, 2010

Study Start

August 1, 2010

Primary Completion

August 1, 2011

Study Completion

December 1, 2011

Last Updated

August 6, 2010

Record last verified: 2010-08

Locations

IL(1)